Olivier Piguet

Olivier Piguet

PhD (University of Sydney); Postdoc (MIT); LicPsych, MA (Clin Neuropsych), PhD, MAPS, FCCN

Neurologist

Over 20 years clinical experience

Male📍 Sydney

About of Olivier Piguet

Olivier Piguet is a Neurologist based in Sydney, working from 94 Mallett Street, Sydney, NSW 2050. Neurology can cover a wide range of brain and nerve conditions, and his work is often focused on people dealing with changes to memory, thinking, movement, and language.


Over time, many patients come in because they’ve noticed something is not quite right. In many cases that can be linked to dementia and related conditions, including Alzheimer’s disease, frontotemporal dementia, and primary progressive aphasia. At times it can also involve other neurological problems that affect day-to-day life, like strokes and vascular dementia.


He also looks after people with movement disorders. This can include Parkinson’s disease, and other conditions where movement and control become harder. Some patients are dealing with motor neuron diseases such as amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), and others may have rare neurodegenerative conditions where symptoms slowly change over months or years.


People may also seek help for issues around speech and understanding, including developmental dysphasia and apraxia. There are also times when doctors and families want guidance when behaviour, personality, or the ability to communicate starts to shift, and they’re trying to find out what’s going on and what can be done next.


Olivier has more than 20 years of clinical experience. His training includes a PhD through the University of Sydney, plus postdoctoral work at MIT. He also holds a LicPsych and MA in Clinical Neuropsychology, along with a Bachelor’s degree in Psychology from the University of Geneva.


Research is part of his background too. He has publications, and he stays up to date with how research can feed back into real care. When needed, this helps with thinking through diagnosis, planning next steps, and supporting families as the picture becomes clearer.


Clinical trials: there isn’t specific trial information listed here, but if a relevant study option is available, it can be discussed as part of care planning.

Education

  • PhD - Doctor of Philosophy, Neuropsychology; University of Sydney; 2000
  • Master's Degree, Clinical Neuropsychology; University of Melbourne; 1992
  • Bachelor's Degree, Psychology; University of Geneva; 1988

Services & Conditions Treated

DementiaFrontotemporal DementiaPrimary Progressive AphasiaAlzheimer's DiseaseAmyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)Developmental Dysphasia FamilialMemory LossPrimary Lateral SclerosisApraxiaBrown SyndromeCorticobasal DegenerationProgressive Supranuclear PalsyProgressive Supranuclear Palsy AtypicalAnosmiaAutism Spectrum DisorderCACH SyndromeFamilial DysautonomiaFamilial HypertriglyceridemiaHypolipoproteinemiaMajor DepressionMovement DisordersParkinson's DiseaseStrokeVascular Dementia

Publications

5 total
The relevance and challenges of cross-cultural studies in primary progressive aphasia.

Journal of the neurological sciences • April 02, 2025

Lucia Fernandez Romero, Jordi Matias Guiu, Olivier Piguet

We thank Drs Saputra and Lidyawati for their interest in our study [1]. We are pleased that our study has sparked interest and discussion in the field of cross-cultural neuropsychology, particularly concerning the impact of linguistic and sociocultural factors on the cognitive profiles of individuals with primary progressive aphasia (PPA).

Risky decision-making in dementia: exploring neural correlates and related clinical symptoms.

Cognitive, Affective & Behavioral Neuroscience • March 05, 2025

Molly-eve Day, David Foxe, Grace Wei, James Burrell, Olivier Piguet, Fiona Kumfor, Stephanie Wong

Background: Appropriately balancing potential risks versus rewards is important for affective decision-making in everyday life. Impaired affective decision-making on risk-taking tasks has been reported in individuals with dementia, but the neural correlates of such deficits, and whether they relate to neuropsychiatric symptoms, such as disinhibition and apathy, have not been directly examined. Methods: Forty-one behavioural-variant frontotemporal dementia (bvFTD), 28 Alzheimer's disease (AD) patients and 42 healthy controls completed the Balloon Analogue Risk Task (BART), which assessed their ability to weigh risks versus rewards to maximise monetary earnings. Informant-reported measures of disinhibition and apathy were completed. All participants underwent structural magnetic resonance imaging brain scans. Results: While bvFTD and AD patients showed some impairments on the BART relative to controls, a high degree of variability was observed within patient groups. Poorer BART performance was associated with bilateral medial prefrontal and orbitofrontal cortex atrophy. A hierarchical cluster analysis revealed four groups of patients, with distinct patterns of BART performance, varying levels of disinhibition and apathy, and divergent patterns of brain atrophy. The group that showed the worst performance on the BART (i.e., collected the least money and popped the most balloons) showed the greatest disinhibition and orbitofrontal cortex atrophy. Conclusions: Our findings highlight the heterogeneous nature of affective decision-making deficits in dementia and uncover important links between BART performance, symptoms of disinhibition and apathy, and orbitofrontal cortex atrophy. Greater understanding of these symptom profiles and underlying neurocognitive mechanisms may help to inform potential management strategies for impaired affective decision-making in dementia.

Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity.

Alzheimer's & Dementia (Amsterdam, Netherlands) • March 04, 2025

Oana Marian, Sophie Matis, Carol Dobson Stone, Woojin Kim, John Kwok, Olivier Piguet, Glenda Halliday, Ramon Landin Romero, Anthony Don

March 04, 2025

Understanding barriers and optimizing socio-cognitive assessment in the diagnosis of neurocognitive disorders.

Journal Of Neuropsychology • December 15, 2024

Chiara Cerami, Marina Boccardi, Claudia Meli, Andrea Panzavolta, Giulia Funghi, Cristina Festari, Stefano Cappa, Thanos Chatzikostopoulos, Christian Chicherio, Florencia Clarens, Fabricio De Oliveira, Francesco Di Lorenzo, Marco Filardi, Agustin Ibanez, Nicola Girtler, Thibaud Lebouvier, Giancarlo Logroscino, Antonella Luca, Sarah Macpherson, Jordi Matias Guiu, Tommaso Piccoli, Olivier Piguet, Simone Pomati, Mirella Russo, Leonardo Sacco, Ann-katrin Schild, Stefano Sensi, Steven Shirk, Marc Sollberger, Miguel Tábuas Pereira, Magda Tsolaki, Esther Van Den Berg, Maxime Bertoux, Fiona Kumfor, Jan Van Den Stock, Kathleen Welsh Bohmer, Alessandra Dodich

Harmonized neuropsychological assessment for neurocognitive disorders (NCDs) is an urgent priority in clinics. Neuropsychology assessments in NCDs seldom include tests exploring social cognitive skills. In 2022, we launched the SIGNATURE initiative to optimize socio-cognitive assessment in NCDs. Here, we report findings from the first initiative phase, including consortium creation and evaluation of the state of the art in socio-cognitive assessment in memory clinics. We developed an ad hoc online survey to explore practices and measures, relevance, and obstacles preventing the use of socio-cognitive testing in clinics. The survey was distributed within the SIGNATURE network. National coordinators were identified to disseminate the survey to local collaborators and scientific societies active in the field of dementia and/or neuropsychology. Data were analysed in aggregate form and stratified by geographical area and variables of interest. Four hundred and thirteen (413) responses from 10 European and Latin American geographical regions were recorded. Responders were balanced between physicians and psychologists. Seventy-eight (78) % of respondents reported no/limited experience with socio-cognitive measures; more than 85% agreed on their relevance in clinics. Ekman-60 faces was the most well-known and/or used task, followed by the Faux-Pas and Reading-the-Mind-in-the-Eyes tests. Lack of clinical measures, assessment time, guidelines, and education/training were reported as main obstacles. Real-life barriers prevent the adoption of socio-cognitive testing in clinics. Bidirectional collaboration between clinicians and researchers is required to address clinical needs and constraints and facilitate consistent socio-cognitive assessment.

Differentiating sporadic frontotemporal dementia from late-onset primary psychiatric disorders.

Brain Communications • December 09, 2024

Sterre C De Boer, Lina Riedl, Simon Braak, Chiara Fenoglio, David Foxe, James Carrick, RamĂłn Landin Romero, Sophie Matis, Zac Chatterton, Ishana Rue, Marie-paule Van Engelen, Jay L Fieldhouse, Mardien Oudega, Sigfried N T Schouws, Welmoed Krudop, Argonde Van Harten, Flora Duits, Sven Van Der Lee, Daniela Galimberti, Janine Diehl Schmid, Glenda Halliday, Simon Ducharme, Yolande A Pijnenburg, Olivier Piguet

Sporadic behavioural variant frontotemporal dementia (bvFTD) is often misdiagnosed as late-onset primary psychiatric disorder (PPD) due to overlapping symptoms and lack of biomarkers. We aimed to identify clinical features that distinguish sporadic bvFTD from PPD. Multi-centre baseline data were retrospectively retrieved and categorized into neuropsychological domains. Logistic regression models and receiver operating characteristic curves were conducted to determine discriminators. Data from 508 sporadic bvFTD and 152 PPD cases were included. Higher scores in cognitive screening [odds ratio (OR): 1.23], facial emotion processing (OR: 1.69), episodic memory (OR: 1.09), animal fluency (OR: 1.17), working memory (OR: 1.18), letter fluency (OR: 1.17) and depressive symptoms (OR: 7.41) were significantly associated with PPD (all Ps ≤ 0.010). Within a combined model, higher scores of letter fluency (OR: 1.47), cognitive screening (OR: 1.72) and lower attention (OR: 0.77) were significantly (all Ps ≤ 0.05) associated with PPD (area under the curve = 0.771). Neuropsychological measurements-letter fluency, cognitive screening and attention-can help distinguish sporadic bvFTD from late-onset PPD. Depressive symptoms and facial emotion processing emerged as potential discriminators, warranting further exploration.

Frequently Asked Questions

What services does Dr Olivier Piguet offer?
Dr Olivier Piguet offers services in neurology, focusing on memory and neurodegenerative conditions such as dementia, Alzheimer’s disease, frontotemporal dementia, and related disorders. He also treats movement disorders and stroke-related issues, among other neurological conditions.
What conditions does he treat?
He treats a range of conditions including dementia (including Alzheimer’s and vascular dementia), frontotemporal dementia, primary progressive aphasia, ALS, Parkinson’s disease and other movement disorders, stroke, and related neurodegenerative conditions.
Where is his clinic located?
His practice is at 94 Mallett Street, Sydney, NSW 2050, Australia.
How long has he worked in clinical practice?
Dr Piguet has over 20 years of clinical experience.
How can I book an appointment?
Booking details are not provided here. Please contact the clinic at the provided address to arrange an appointment.
What is his background or qualifications?
Dr Piguet has a PhD in Neuropsychology from the University of Sydney, plus postdoctoral work at MIT, and holds LicPsych, MA in Clinical Neuropsychology, PhD, MAPS, and FCCN.